aSMDC
Phase 3Biologic
aSMDC is one of 15 biologic programs targeting Fecal Incontinence. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Fecal Incontinence
#DrugCompanyPhaseTrials
1Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Flagyl
DDePuy Orthopaedics
Approved
Catapres
Boehringer IngelheimPhase 3
Welchol
CCosette Pharmaceuticals, Inc.
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Imodium
KKenvue Brands
Phase 2
Ramosetron
AstellasPhase 2
Viberzi
AbbViePhase 2
Psyllium
SSeoul National University Hospital
Phase 3
Botulinum Toxin a
GSKPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for aSMDC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- IInnovacell GmbH